OPWM
RXRX icon

Oxinas Partners Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Oxinas Partners Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,250
Closed -$74.1K – 125
2024
Q3 		$74.1K Sell
11,250
-5,650
-33% -$40.5K 0.05% 113
2024
Q2 		$127K Buy
16,900
+4,650
+38% +$40.6K 0.08% 122
2024
Q1 		$122K Buy
+12,250
New +$136K 0.08% 126

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Oxinas Partners Wealth Management's RXRX Position: Q4 2024 in Review

Oxinas Partners Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 11,250 shares — an estimated $74.1K sold.

Oxinas Partners Wealth Management first reported a position in RXRX in Q1 2024 and held it in 3 quarters. The position peaked at $127K in Q2 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • Oxinas Partners Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Oxinas Partners Wealth Management sold 11,250 Recursion Pharmaceuticals shares in Q4 2024, an estimated $74.1K.
  • Oxinas Partners Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Oxinas Partners Wealth Management's Recursion Pharmaceuticals position peaked at $127K in Q2 2024.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Oxinas Partners Wealth Management's 13F filing for Q4 2024, filed 17 Jan 2025.